Ackrell Capital Cannabis Investment Report – Regulatory Overview (Dec 2017)

The passage is a generic regulatory summary of cannabis‑related products and FDA approval processes. It contains no specific actors, transactions, dates, or allegations that could be pursued as an inv Defines how cannabis products may be classified under the FD&C Act. Outlines FDA drug approval steps (IND, clinical trials, NDA). Mentions Ackrell Capital, LLC as the report author.